Register entry
- Registered sites
- 0
- Active NDC listings
- 67
- Labeller names
- 4
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
6767 active NDC listings: 39 human prescription drug, 28 plasma derivative. By marketing category: BLA 67.
| Dosage form | NDCs |
|---|---|
| kit | 51 |
| liquid | 11 |
| solution | 3 |
| injection, powder, lyophilized, for solution | 1 |
| injection, solution | 1 |
| Route | NDCs |
|---|---|
| intravenous | 8 |
| subcutaneous | 8 |
| intramuscular | 1 |
| Labeller name on the listing | NDCs |
|---|---|
| csl behring | 39 |
| csl behring ag | 14 |
| csl behring gmbh | 11 |
| csl behring llc | 3 |
Catalogue
Marketed products
67| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| ALBURX | ALBUMIN (HUMAN) | solution, intravenous | 44206-310BLA |
| AlbuRx | ALBUMIN (HUMAN) | solution, intravenous | 44206-251BLA |
| Berinert | HUMAN C1-ESTERASE INHIBITOR | kit | 63833-825BLA |
| Corifact | Factor XIII Concentrate (Human) | kit | 63833-518BLA |
| HAEGARDA C1 Esterase Inhibitor Subcutaneous (Human) | HUMAN C1-ESTERASE INHIBITOR | kit | 63833-828BLA |
| HAEGARDA C1 Esterase Inhibitor Subcutaneous (Human) | HUMAN C1-ESTERASE INHIBITOR | kit | 63833-829BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0100BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0110BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0120BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0130BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0140BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0150BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0160BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0170BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0180BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0190BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0200BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0210BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0220BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0230BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0240BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0250BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0260BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0270BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0280BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0290BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0300BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0310BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0320BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0330BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0340BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0350BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0360BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0370BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0380BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0390BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0400BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0410BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0420BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0430BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0440BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0450BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0460BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0470BLA |
| HEMGENIX | etranacogene dezaparvovec | kit | 0053-0480BLA |
| Hizentra | HUMAN IMMUNOGLOBULIN G | liquid, subcutaneous | 44206-451BLA |
| Hizentra | HUMAN IMMUNOGLOBULIN G | liquid, subcutaneous | 44206-452BLA |
| Hizentra | HUMAN IMMUNOGLOBULIN G | liquid, subcutaneous | 44206-454BLA |
| Hizentra | HUMAN IMMUNOGLOBULIN G | liquid, subcutaneous | 44206-455BLA |
| Hizentra | HUMAN IMMUNOGLOBULIN G | liquid, subcutaneous | 44206-456BLA |
| Hizentra | HUMAN IMMUNOGLOBULIN G | liquid, subcutaneous | 44206-457BLA |
| Hizentra | HUMAN IMMUNOGLOBULIN G | liquid, subcutaneous | 44206-458BLA |
| Humate-P | antihemophilic factor/von willebrand factor complex (human) | kit | 63833-615BLA |
| Humate-P | antihemophilic factor/von willebrand factor complex (human) | kit | 63833-616BLA |
| Humate-P | antihemophilic factor/von willebrand factor complex (human) | kit | 63833-617BLA |
| Kcentra | PROTHROMBIN, COAGULATION FACTOR VII HUMAN, COAGULATION FACTOR IX HUMAN, COAGULATION FACTOR X HUMAN, Protein C, Protein S Human, and Water | kit | 63833-386BLA |
| Kcentra | PROTHROMBIN, COAGULATION FACTOR VII HUMAN, COAGULATION FACTOR IX HUMAN, COAGULATION FACTOR X HUMAN, Protein C, Protein S Human, and Water | kit | 63833-387BLA |
| Privigen | Human Immunoglobulin G | liquid, intravenous | 44206-436BLA |
| Privigen | Human Immunoglobulin G | liquid, intravenous | 44206-437BLA |
| Privigen | Human Immunoglobulin G | liquid, intravenous | 44206-438BLA |
| Privigen | Human Immunoglobulin G | liquid, intravenous | 44206-439BLA |
| Rhophylac | HUMAN RHO(D) IMMUNE GLOBULIN | solution, intramuscular, intravenous | 44206-300BLA |
| RiaSTAP | FIBRINOGEN HUMAN | injection, powder, lyophilized, for solution, intravenous | 63833-891BLA |
| Riastap | FIBRINOGEN HUMAN | injection, solution, subcutaneous | 63833-892BLA |
| ZEMAIRA | .ALPHA.1-PROTEINASE INHIBITOR HUMAN | kit | 0053-7202BLA |
| ZEMAIRA | .ALPHA.1-PROTEINASE INHIBITOR HUMAN | kit | 0053-7203BLA |
| Zemaira | alpha-1-proteinase inhibitor human | kit | 0053-7201BLA |
Enquiry
Common questions
- Is CSL Behring GmbH FDA approved?
- CSL Behring GmbH holds no registered establishment of its own; 67 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does CSL Behring GmbH make?
- 67 products are listed under CSL Behring GmbH in the openFDA NDC Directory, most often as kit; liquid; solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.